Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JSKN 003 (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

  • 30 Dec 2024 Planned number of patients changed from 300 to 725.
  • 30 Dec 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
  • 04 Jun 2024 Results (n=46, data cut-off: 5 Jan 2024) of the phase 1 part assessing MTD, DLT, safety, efficacy and pharmacokinetics of JSKN003 in heavily pretreated patients with advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top